All contributors
Onconephrology contributor
Sise, Meghan E
Primarily Anticancer drug nephrotoxicity#27 of 46 recognizedHonor roll
- #2 in Checkpoint-inhibitor kidney injury
31
Clinical papers
1,521
Citations (iCite)
2 / 18
First / senior author
2019–2026
Active years
Output over time
Clinical corpus papers per year — peak 7 in 2021.
- 2019: 3 papers
- 2020: 3 papers
- 2021: 7 papers
- 2022: 6 papers
- 2023: 5 papers
- 2024: 2 papers
- 2025: 4 papers
- 2026: 1 paper
20192026
Subfield mix
Clinical papers by onconephrology subfield (a paper can count in more than one).
Anticancer drug nephrotoxicity20
Checkpoint-inhibitor kidney injury17
Onco-nephrology (general)7
Cellular therapy renal effects3
Anti-VEGF / TKI renal effects1
Frequent co-authors
Other recognized contributors who most often share corpus papers with Sise (shared-paper count).
Agents they study
Catalog agents whose clinical kidney literature lists Sise among the leading contributors (clinical-paper count on that agent).
Verify
Representative recent papers, and this author’s full PubMed bibliography.
A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,541-article corpus (regenerated 2026-10-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.